Zymergen’s Collapse: Market Hype, Investor Losses, and a $30 Million SEC Penalty
When Zymergen went public in April 2021, it looked like another Silicon Valley success story in the making. The synthetic biology company raised about $530 million in its Nasdaq debut and carried